High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis

被引：53

作者：

Lemesle, G. ^{[1
,2
,3
]}

Schurtz, G. ^{[1
]}

Bauters, C. ^{[1
,2
,3
]}

Hamon, M. ^{[4
,5
]}

机构：

[1] CHRU Lille, F-59037 Lille, France

[2] Inst Pasteur, Inserm U744, F-59019 Lille, France

[3] Univ Lille, Fac Med, Lille, France

[4] Ctr Hosp Univ Caen, Caen, France

[5] Fac Med Caen, Caen, France

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷 / 06期

关键词：

acute coronary syndrome; antiplatelet agents; coronary artery disease; percutaneous coronary intervention; platelet function tests; ACUTE CORONARY SYNDROME; ASPIRIN-TREATED PATIENTS; MYOCARDIAL-INFARCTION; RANDOMIZED ASSESSMENT; DOSE CLOPIDOGREL; ACHIEVES GREATER; INHIBITION; INTERVENTION; EVENTS; IMPACT;

D O I：

10.1111/jth.12907

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundTicagrelor and prasugrel have shown superiority over clopidogrel. However, it remains unclear if one is superior to another regarding on-treatment platelet reactivity. ObjectivesTo compare the impact of ticagrelor and prasugrel on high on-treatment platelet reactivity (HTPR). MethodsThe PubMed and Cochrane databases were searched for eligible studies in December 2014. Studies were eligible if they compared ticagrelor and prasugrel regarding high on-treatment platelet reactivity (HTPR). Pooled estimates were calculated by using a random-effects model with 95% confidence intervals. ResultsWe included 14 studies and 1822 patients: 805 and 1017 in the ticagrelor and prasugrel groups, respectively. The rate of HTPR was significantly lower in the ticagrelor group: 1.5% vs. 9.8% (RR=0.27 [0.14-0.50]). The pre-specified analysis focusing on randomized trials (n=10) showed consistent results (RR=0.27 [0.12-0.60]). ConclusionOur results suggest that ticagrelor allows a higher platelet reactivity inhibition as compared with prasugrel and leads to a further decrease in the rate of HTPR.

引用

收藏

页码：931 / 942

页数：12

相关论文

共 42 条

[21] Platelet reactivity in patients and recurrent events post-stenting - Results of the PREPARE POST-STENTlNG study [J].

Gurbel, PA ;

Bliden, KP ;

Guyer, K ;

Cho, PW ;

Zaman, KA ;

Kreutz, RP ;

Bassi, AK ;

Tantry, US .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (10) :1820-1826

[22] Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies The RESPOND Study [J].

Gurbel, Paul A. ;

Bliden, Kevin P. ;

Butler, Kathleen ;

Antonino, Mark J. ;

Wei, Cheryl ;

Teng, Renli ;

Rasmussen, Lars ;

Storey, Robert F. ;

Nielsen, Tonny ;

Eikelboom, John W. ;

Sabe-Affaki, Georges ;

Husted, Steen ;

Kereiakes, Dean J. ;

Henderson, David ;

Patel, Dharmendra V. ;

Tantry, Udaya S. .

CIRCULATION, 2010, 121 (10) :1188-1199

[23] High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest [J].

Ibrahim, K. ;

Christoph, M. ;

Schmeinck, S. ;

Schmieder, K. ;

Steiding, K. ;

Schoener, L. ;

Pfluecke, C. ;

Quick, S. ;

Mues, C. ;

Jellinghaus, S. ;

Wunderlich, C. ;

Strasser, R. H. ;

Kolschmann, S. .

RESUSCITATION, 2014, 85 (05) :649-656

[24] Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies [J].

Jeong, Young-Hoon ;

Bliden, Kevin P. ;

Antonino, Mark J. ;

Park, Ki-Soo ;

Tantry, Udaya S. ;

Gurbel, Paul A. .

AMERICAN HEART JOURNAL, 2012, 164 (01) :35-42

[25] Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease [J].

Jernberg, T ;

Payne, CD ;

Winters, KJ ;

Darstein, C ;

Brandt, JT ;

Jakubowski, JA ;

Naganuma, H ;

Siegbahn, A ;

Wallentin, L .

EUROPEAN HEART JOURNAL, 2006, 27 (10) :1166-1173

[26] Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome [J].

Laine, Marc ;

Frere, Corinne ;

Toesca, Richard ;

Berbis, Julie ;

Barnay, Pierre ;

Pansieri, Michel ;

Michelet, Pierre ;

Bessereau, Jacques ;

Camilleri, Elise ;

Ronsin, Olivia ;

Helal, Olfa ;

Paganelli, Franck ;

Dignat-George, Francoise ;

Bonello, Laurent .

THROMBOSIS AND HAEMOSTASIS, 2014, 111 (02) :273-278

[27] Poor agreement between light transmission aggregometry, Verify Now P2Y12 and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: A potential explanation of negative results of recent randomized trials [J].

Lemesle, Gilles ;

Landel, Jean-Baptiste ;

Bauters, Anne ;

Delhaye, Cedric ;

Bonello, Laurent ;

Sudre, Arnaud ;

Susen, Sophie ;

Bauters, Christophe ;

Lablanche, Jean-Marc .

PLATELETS, 2014, 25 (07) :499-505

[28] Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: Comparative effects of prasugrel and ticagrelor on platelet reactivity [J].

Lhermusier, T. ;

Voisin, S. ;

Murat, G. ;

Mejean, S. ;

Garcia, C. ;

Bataille, V. ;

Lipinski, M. J. ;

Carrie, D. ;

Sie, P. .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 174 (03) :874-876

[29] Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction [J].

Matetzky, S ;

Shenkman, B ;

Guetta, V ;

Schechter, M ;

Bienart, R ;

Goldenberg, I ;

Novikov, I ;

Pres, H ;

Savion, N ;

Varon, D ;

Hod, H .

CIRCULATION, 2004, 109 (25) :3171-3175

[30] Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement [J].

Moher, D ;

Cook, DJ ;

Eastwood, S ;

Olkin, I ;

Rennie, D ;

Stroup, DF .

LANCET, 1999, 354 (9193) :1896-1900

← 1 2 3 4 5 →